Evidence map›Paper›PMID 35312859›Full record

ArticleWiener klinische Wochenschrift2022

Establishment of a virtual transborder tumor board for cancer patients in Central and Southeastern Europe : An initiative of the Central European Cooperative Oncology Group (CECOG).

Christiane Thallinger, Peter Berzinec, Emina Bicakcic, Adelina Dan, Gabriella Fabian, Laurentia Nicoletta Gales, Cvetka Grasic Kuhar, Urska Janzic, Zsusanna Kahan, Marina Mencinger and 7 more

Abstract read
In one paragraph

Article in Wiener klinische Wochenschrift, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors.

Christiane ThallingerCentral European Cooperative Oncology Group, Ohmanngasse 26, 1190, Vienna, Austria. christiane.thallinger@cancer-center.cc.ORCID http://orcid.org/0000-0003-2714-535X
Peter BerzinecDepartment of Oncology at the Hospital of St Zoerardus Zobor, Nitra, Teaching Base of the Slovak Medical University Bratislava, Bratislava, Slovakia.
Emina BicakcicOncology Unit, Clinical Center of Sarajevo University, Sarajevo, Bosnia and Herzegovina.
Adelina DanDepartment of Medical Oncology at Ion Chiricuta Institute of Oncology, Cluj-Napoca, Romania.
Gabriella FabianDepartment of Oncotherapy, University of Szeged, Szeged, Hungary.
Laurentia Nicoletta GalesDepartment of Oncology at UMF "Carol Davila", Bucharest, Romania.
Cvetka Grasic KuharDepartment of Medical Oncology, Institute of Oncology Ljubljana, Ljubljana, Slovenia.
Urska JanzicDepartment of Medical Oncology, University Clinic Golnik, Golnik, Slovenia.
Zsusanna KahanDepartment of Oncotherapy, University of Szeged, Szeged, Hungary.
Marina MencingerDepartment of Medical Oncology, Institute of Oncology Ljubljana, Ljubljana, Slovenia.
George PenthedourakisDepartment of Medical Oncology, University Hospital of Ioannina, Ioannina, Greece.
Joseph Sgouros3rd Medical Oncology Department, "Agii Anargiri" General Hospital and Cancer Center, Athens, Greece.
Luka SimeticDepartment of Oncology, University Hospital Centre Zagreb, Zagreb, Croatia.
Daniela SirbuOncohelp Oncology Center, Timisoara, Romania.
Milan VosmikDepartment of Oncology and Radiotherapy, University Hospital Hradec Králové, Hradec Králové, Czech Republic.
Anna WronaDepartment of Oncology and Radiotherapy, Medical University Gdansk, Gdansk, Poland.
Christoph ZielinskiCentral European Cooperative Oncology Group, Ohmanngasse 26, 1190, Vienna, Austria.

Funding

Pfizer Inc. Grant ID 34580627
6 · The paper itself

Abstract

purposeTo establish a transborder virtual tumor board (VTB) fostering state-of-the-art management of cancer patients by exchanging knowledge and expertise among oncologists in Central and Southeastern Europe (CEE).

methodsWe established and implemented a VTB based on the WebEx platform. This allowed for password-protected and secure upload of patient cases to be presented and discussed among colleagues from various oncology centers scattered throughout CEE in order to arrive at a recommendation for further diagnoses and/or treatment.

resultsA total of 73 cases from 16 oncology centers located in 11 CEE countries were uploaded by 22 physicians; 71 were discussed over the course of 17 virtual meetings between June 2018 and May 2019 and 12 different kinds of malignant diseases were discussed with lung cancer (46.6%), melanoma (19.2%) and bladder cancer (13.6%) being the most commonly presented tumor entities. Of the discussed patients, 93.3% had stage IV disease at the time of presentation, 62.6% received chemotherapy or targeted treatment and 67.1% were treated with immune checkpoint inhibitors (ICPIs). The most common causes for presentation and discussion of patient cases were related to the use of ICPIs (80%).

conclusionWhen the need for expertise exceeds locally available resources, web-based VTBs provide a feasible way to discuss patient cases and arrive at conclusions regarding diagnoses and/or treatment across large geographic distances. Moreover, VTBs provide an innovative way for proper, state-of-the-art management of patients with malignant diseases in times of social distancing and the resulting need for restricted interaction during the current SARS-CoV‑2 (severe acute respiratory syndrome coronavirus type 2) pandemic.

Indexed as

COVID-19Lung NeoplasmsEuropeHumansImmune Checkpoint InhibitorsSARS-CoV-2Immune Checkpoint InhibitorsCECOGCentral and Southeastern EuropeImmune checkpoint inhibitorsMalignant diseasesRemote tumor board

Identifiers

PMID35312859
PMCPMC8936045

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.